作　　者： (文睿婷）; (黄琳）; (于芝颖）; (冯婉玉）;

机构地区： 北京大学人民医院药剂科,北京100044

出　　处： 《中国临床药理学杂志》 2017年第17期1710-1712,共3页

摘　　要： 目的系统评价甲基多巴和拉贝洛尔治疗妊娠期高血压疾病的有效性及安全性。方法检索Med Line,Cochrane Library,EMbase,中国知网、万方、维普等数据库中公开发表的甲基多巴和拉贝洛尔治疗妊娠期高血压疾病的随机对照研究,试验组予以甲基多巴治疗,对照组予以拉贝洛尔治疗。用Rev Man 5.3软件进行Meta分析。结果共纳入10项随机对照研究,共计1285例患者。试验组和对照组的重度高血压发生率分别为6.62%和12.21%,蛋白尿发生率分别为15.57%和8.52%,药物不良反应发生率分别为21.82%和25.63%,胎儿/婴儿死亡率分别为4.19%和2.84%,差异均无统计学意义(均P>0.05)。试验组的浆黏度明显低于对照组,差异有统计学意义(RR=0.77,95%CI=0.64~0.90,P<0.001)。结论甲基多巴和拉贝洛尔治疗妊娠期高血压疾病降压疗效和安全性相当,但甲基多巴在改善血浆黏度上明显优于拉贝洛尔。 Objective To evaluate the efficacy and safety of methyldopa and labetalol in treating hypertension disorders in pregnancy. Methods Databases of MedLine, Cochrane Library, EMbase, CNKI, Wanfang, and VIP were searched for published randomized controlled trials （RCTs） on hypertension disorders in pregnancy with methyldopa as treat- ment group and labetalol as control group. Meta - analysis was conducted by RevMan 5. $ software. Results A total of 10 RCTs involving 1285 patients were included. Rates of severe hypertension in treatment group and control group were 6. 62% and 12. 21%, respectively. Rates of pro- teinuria were 15.57% and 8.52%, rates of adverse drug reaction were 21.82% and 25.63%, rates of fetal/infant death were 4. 19% and 2. 84%. The results of Meta - analysis revealed that there were no signi- ficant differences in the above parameters between treatment and control groups. However, plasma viscosity was significantly lower in treatment group compared with that in control group （ RR = 0. 77, 95% CI = 0. 64 -0. 90, P 〈 0. 001 ）. Conclusion Methyldopa and labetalol are equally effective and safe in treating hypertension disorders in pregnancy, while meth,cldopa is more effective in reducing plasma viscosity.

关 键 词： 甲基多巴 拉贝洛尔 高血压 妊娠 分析